

17 April 2025

## Argent BioPharma Ltd. (Argent BioPharma or the Company)

### Operational and Clinical Development Update

#### Highlights:

- **Completion of organisational restructuring and transfer of EU GMP manufacturing sites in Slovenia and Malta to third-party operators**
- **Significant reduction in operational expenditure, saving over USD \$1 million annually**
- **Strategic shift to proprietary, internally developed IP, eliminating reliance on third-party licenses**
- **Core clinical development now focused on neuro-immune therapeutic areas: CNS and autoimmune disorders**
- **Approval and first purchase orders for CannEpil® and CogniCann® in Germany, alongside continued demand in Ireland**

Argent BioPharma Ltd. (ASX: RGT) is pleased to provide an update on the Company's ongoing transformation strategy, highlighted by the successful completion of a full operational restructuring across its European manufacturing operations. The Company has transitioned its EU GMP-certified production sites in Slovenia and Malta to third-party operators—resulting in annual operational expenditure (OPEX) savings of over USD \$1 million.

This strategic move enables Argent BioPharma to concentrate resources on high-impact clinical development and in-house innovation, while leveraging trusted external partners for scalable and compliant manufacturing operations.


A cornerstone of the Company's forward strategy is the shift toward fully proprietary intellectual property. Argent BioPharma has successfully transitioned away from reliance on third-party IP licenses, enhancing its long-term value and operational independence. This evolution supports a focused pipeline in neuroimmune disorders, specifically targeting central nervous system (CNS) conditions—such as epilepsy, dementia, Alzheimer's disease, and Parkinson's disease—as well as autoimmune diseases, including immune modulation and anti-inflammatory treatments.

Lead drug candidates such as CannEpil®, CogniCann®, and CimetrA® exemplify this strategy. These therapeutics are built upon Argent's proprietary Neuro-Immune Modulatory (NIM) platform, which combines targeted science, nano-delivery technologies, and immune system engagement.

In tandem with clinical development, Argent BioPharma has made significant strides in its commercial strategy. While the Company previously announced regulatory approval for CannEpil® and CogniCann® prescriptions in Germany, it is now pleased to confirm the receipt of initial purchase orders from that market. This follows sustained commercial success in Ireland, where CannEpil® continues to generate strong demand from both patients and healthcare providers.

These milestones reflect Argent BioPharma's commitment to advancing effective neuroimmune therapies while operating under a lean, IP-driven model designed to accelerate clinical progress and commercial growth across Europe and beyond.

-ENDS-



Authorised for release by the board of directors, for further information please contact:

**Argent BioPharma**

Roby Zomer  
CEO & Managing Director  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**Argent BioPharma**

Rowan Harland  
Company Secretary  
+61 8 6555 2950  
[info@argentbiopharma.com](mailto:info@argentbiopharma.com)

**About Argent BioPharma**

Argent BioPharma Limited (ASX: RGT) is an innovative clinical-stage biopharmaceutical company specialising in neuroimmunology and advanced nanomedicine. By leveraging the Neuro-Immune Modulatory (NIM) System, Argent BioPharma's robust pipeline—including CannEpi®, CogniCann®, and Cimetra®—targets CNS disorders and immune-related conditions. With a commitment to science-driven innovation, Argent BioPharma is shaping the future of cannabinoid-based therapeutics and neuroimmune modulation.

Follow us through our social media channels:

LinkedIn: Argent BioPharma

Twitter: @ArgentBioPharma

Facebook: Argent BioPharma



**Argent BioPharma Ltd**  
Suite 1, 295 Rokeby Road  
Subiaco, WA 6008, Australia

 +61 8 6555 2950

 [info@argentbiopharma.com](mailto:info@argentbiopharma.com)